ClinicalTrials.gg
CompletedNCT03736369Updated Sep 3, 2020

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

A Phase 3 interventional study of DWP14012 40mg and DWP14012 40mg placebo in Erosive Esophagitis, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-03.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
263
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Esophagitis with a site in Korea, Republic of — none open to participants now, none under way, none of them phase 3. Esophagitis · Korea, Republic of.

Enrollment
8th of 12
263 · median 290
Started
2018
the only one that year
Phase 3
9 of 12
none open now
Registered
6th of 12
by date
Lead sponsor
3 of 12
Daewoong Pharmaceutical Co. LTD.

Among the 12 studies in Esophagitis with a site in Korea, Republic of, this one is the 8th largest by enrollment, is the only one that started in 2018, is one of 9 in phase 3, and was the 6th registered.

Esophagitis

123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.

Browse Esophagitis studies →

Open to participants now

None of the 12 studies in Esophagitis with a site in Korea, Republic of is open now. The open studies under Esophagitis, anywhere →

Who these studies take

Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Esophagitis with a site in Korea, Republic of as a file.
02

Study summary

The purpose of study is to confirm the efficacy of DWP14012 Xmg, Once daily, compared to esomeprazole 40mg in patients with erosive gastroesophageal reflux disease.

03

Conditions studied

  • Erosive Esophagitis

Browse trials for

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults between 20 and 75 years old based on the date of written agreement
  • Those who have been diagnosed with erosive gastroesophageal reflux disease(EGRD) of LA Grade A-D on the upper gastrointestinal endoscopy
  • Those who experienced symptoms of heartburn or acid regurgitation within the last 7 days

Exclusion criteria

Exclusion Criteria:

  • Those who have undergone gastric acid suppression or gastric, esophageal surgery
  • Those who with liver, kidney, nervous system, respiratory, endocrine, hematologic, cardiovascular, urinary system disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
263 participants (actual)

Study arms

  • Experimental
    DWP14012 40mg

    Orally, once daily

    Drug: DWP14012 40mg · Drug: Esomeprazole 40mg placebo

  • Active comparator
    Esomeprazole 40mg

    Orally, once daily

    Drug: DWP14012 40mg placebo · Drug: Esomeprazole 40mg

Interventions

  • DWP14012 40mg, tablet, orally, once daily for up to 8 weeks

  • DrugDWP14012 40mg placebo

    DWP14012 40mg placebo-matching tablet, orally, once daily for up to 8 weeks

  • Esomeprazole 40mg tablet, orally, once daily for up to 8 weeks

    Also known as: Nexium 40mg

  • DrugEsomeprazole 40mg placebo

    Esomeprazole 40mg placebo-matching tablet, orally, once daily for up to 8 weeks

    Also known as: Nexium 40mg placebo

06

What researchers measure

Primary outcomes

  1. Cumulative healing rate of erosive esophagitis at 8week by endoscopy

    Time frame: at 8week

Secondary outcomes

  1. Cumulative healing rate of erosive esophagitis at 4week by endoscopy

    Time frame: at 4week

  2. Reflux disease symptom assessment using RDQ(Reflux disease questionnaire)

    Mean change of the frequency or severity of main symptoms

    Time frame: at 4week and 8week

  3. Quality of Life assessment using GERD-HRQL(GERD-Health related quality life)

    Mean change of the total score of GERD-HRQL

    Time frame: at 4week and 8week

07

Study locations

1 site
  • Hanyang University Medical Center
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Aug 2019, 7 months.

Of 18 phase 3 interventional studies under Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2018
First posted
Nov 9, 2018
StartActual
Dec 13, 2018
Primary completionActual
Aug 7, 2019
CompletionActual
Aug 7, 2019
Last update
Sep 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03736369
Responsible party
Sponsor
First posted
Nov 9, 2018
Start date
Dec 13, 2018
Primary completion
Aug 7, 2019
Completion
Aug 7, 2019
Last update
Sep 3, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion